Navigation Links
3SBio Inc. Announces Extraordinary General Meeting of Shareholders
Date:3/24/2013

SHENYANG, China, March 24, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at 10:00 a.m. on April 25, 2013 (Beijing time).  The meeting will be held at 15/A-D, Huaxin International Tower, No. 219, Qingnian Ave., Shenhe District, Shenyang 110016, People's Republic of China, to consider and vote on the proposal to adopt the previously announced agreement and plan of merger dated February 8, 2013, among Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub"), and the Company (the "Merger Agreement"), pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of Parent (the "Merger").  If completed, the Merger would result in the Company becoming a privately-held company and its American Depository Shares ("ADSs") would no longer be listed on the NASDAQ Global Market.  The Company's Board of Directors, acting upon the unanimous recommendation of an independent committee formed by the Board of Directors, approved the Merger Agreement and the merger contemplated in the Merger Agreement and resolved to recommend that the Company's shareholders vote to approve and authorize the Merger Agreement and the merger.

Shareholders of record as of the close of business in the Cayman Islands on April 12, 2013 will be entitled to vote at the EGM.  The record date for ADS holders entitled to instruct JPMorgan Chase Bank, N.A., the ADS depositary, to vote the shares represented by the ADSs is the close of business in New York City on March 25, 2013.  Additional information regarding the EGM and the Merger Agreement can be found in the Transaction Statement on Schedule 13E-3, and the proxy statement attached as Exhibit (a)-(1) thereto, filed with the Securities and Exchange Commission (the "SEC"), which can be obtained from the SEC's website (http://www.sec.gov).

INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.

This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that have been or will be made with the SEC.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people.  Shares trade in the form of ADSs on the NASDAQ global market under the ticker symbol "SSRX".  Please see www.3SBio.com for more information.

For investor and media inquiries, please contact: 

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. 3SBio Inc. To Present at the DB Access Asia Conference 2012
3. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
4. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
5. 3SBio Inc. Announces Changes to Its Board of Directors
6. Apexigen Announces the Filing of an IND by its Partner, 3SBio
7. 3SBio Inc. to Hold 2012 Annual General Meeting on October 10, 2012
8. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
9. 3SBio Independent Committee Selects Legal Counsel in connection with Going Private Proposal
10. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
11. 3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Mass. , Feb. 9, 2016  Insulet Corporation (NASDAQ: ... tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s Board ... of nine directors, eight of whom are independent. ... 40 years of audit and finance experience and a deep ...
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... Bermuda, Feb. 9, 2016  Axovant Sciences Ltd. ... on the treatment of dementia, today announced further ... cognitive, behavioral and functional aspects of Lewy body ... in the U.S. Two out of the three ... expected to start later this quarter. In addition, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the ... ended December 31, 2015 on Monday, February 29, 2016 after the market closes. , ... the release at 4:30 PM ET. Investors interested in participating by phone are invited ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... For ... in new book , Pioneering book "Better with Age: The Ultimate Guide to Brain ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX ... accessories. These PEEK-lined stainless steel (PLS) columns combine the strength of traditional stainless ... the integrity of biological samples while operating at ultra-high pressures of 20,000 psi. ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... The recreational ... cannabis enthusiasts in the state still face a lot of restrictions as to where ... is intended for private, personal use” and that cannabis “may not be consumed openly ...
(Date:2/10/2016)... ... 2016 , ... Ross A. Clevens, MD, FACS , ... a new addition to their growing practice. Beginning this month, Teresa Imperiale-Westerfield, a ... performing cosmetic procedures including injectables, fillers and laser treatments. A master ...
Breaking Medicine News(10 mins):